Viral infections associated with haemophagocytic syndrome

Nadine Rouphael, Emory University
Abeer Moanna, Emory University
Jesse Jacob, Emory University
Helmut Albrecht, University of South Carolina

Journal Title: Reviews in Medical Virology
Volume: Volume 20, Number 2
Publisher: Wiley: 12 months | 2010-03-01, Pages 93-105
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1002/rmv.638
Permanent URL: https://pid.emory.edu/ark:/25593/vf8rm

Final published version: http://dx.doi.org/10.1002/rmv.638

Copyright information:
Copyright © 2010 John Wiley & Sons, Ltd.
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).

Accessed November 9, 2022 8:06 AM EST
Viral infections associated with haemophagocytic syndrome

Nadine Rouphael Maakaroun1+,1, Abeer Moanna2, Jesse T Jacob1+ and Helmut Albrecht3+

1Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30303, USA
2Division of Infectious Diseases, Emory University School of Medicine, Veterans Affairs Medical Center, Decatur, GA 30033, USA
3Division of Infectious Diseases, University of South Carolina, Columbia, SC 29203 USA

SUMMARY

Haemophagocytic syndrome (HPS) or haemophagocytic lymphohistiocytosis (HLH) is a rare disease caused by a dysfunction of cytotoxic T cells and NK cells. This T cell/NK cell dysregulation causes an aberrant cytokine release, resulting in proliferation/activation of histiocytes with subsequent haemophagocytosis. Histiocytic infiltration of the reticuloendothelial system results in hepatomegaly, splenomegaly, lymphadenopathy and pancytopenia ultimately leading to multiple organ dysfunctions. Common clinical features include high fevers despite broad spectrum antimicrobials, maculopapular rash, neurological symptoms, coagulopathy and abnormal liver function tests. Haemophagocytic syndrome can be either primary, i.e. due to an underlying genetic defect or secondary, associated with malignancies, autoimmune diseases (also called macrophage activation syndrome) or infections. Infectious triggers are most commonly due to viral infections mainly of the herpes group, with EBV being the most common cause. HPS can be fatal if untreated. Early recognition of the clinical presentation and laboratory abnormalities associated with HPS and prompt initiation of treatment can be life saving. HPS triggered by viral infections generally does not respond to specific antiviral therapy but may be treated with immunosuppressive/immunomodulatory agents and, in refractory cases, with bone marrow transplantation. Copyright © 2010 John Wiley & Sons, Ltd.

Received: 20 August 2009; Revised: 18 September 2009; Accepted: 1 October 2009

DEFINITION, EPIDEMIOLOGY AND CLASSIFICATION

Haemophagocytic syndrome (HPS), also called haemophagocytic lymphohistiocytosis (HLH) [1], is characterised by impaired or absent activity of NK cells and cytotoxic T-cells leading to cytokine dysregulation with proliferation and activation of histiocytes. HPS results in multiorgan dysfunction and haemophagocytosis within the reticuloendothelial system characterised by pancytopenia and organomegaly [1]. If untreated, HPS can be fatal. HPS was first described by Scott and Robb-Smith in 1939 [2] who termed it ‘histiocytic medullary reticulosis’. Virus-associated HPS (VAHS) was first characterised in 1979 by Risdall in a case series of 19 patients [3].

The incidence of HPS is difficult to estimate since the syndrome is certainly underdiagnosed. A nationwide survey of HPS in Japan, where a large number of HPS studies have been done, reported [4] an annual incidence of 1 in 800 000. HPS can be divided into primary or genetic HPS and secondary or reactive HPS (Table 1). Primary HPS usually occurs early in life and is associated...
Table 1. Classification of HPS

| Primary or genetic | Secondary or reactive |
|--------------------|-----------------------|
| Familial form      | Macrophage activation syndrome |
| Forms associated with immune deficiency syndromes | (MAS) associated with autoimmune diseases |
| Malignancy associated HLH | Especially lymphoma-associated hematophagocytic syndrome (LAHS) |
| (especially lymphoma-associated hematophagocytic syndrome (LAHS)) | Infection associated HLH (IAHS) |

with a higher mortality rate, while secondary HPS occurs later in life and generally carries a better prognosis. This distinction is not categorical as primary HPS can occur later in life [5], may be triggered by infections, [6] and may not be associated (up to 50–60% [7]) with a ‘typical’ genetic mutation.

Genetic HPS

The familial form of HLH (FHLH) was first described in 1952 [8] by Farquhar and Claireaux. FHLH is an autosomal recessive disorder estimated to occur in 1 out of 30,000 to 50,000 births [9,10] and in 70–80% of cases manifests in the first year of life. Other forms of genetic HPS are associated with immune deficiency syndromes including Chediak–Higashi syndrome, Griscelli syndrome, X-linked lymphoproliferative syndrome (XLP), Wiskott–Aldrich syndrome, severe combined immunodeficiency, lysinuric protein intolerance and Hermansky–Pudlak syndrome.

Reactive HPS

The true incidence of reactive HPS is difficult to define. Reactive HPS can be divided into three categories:

1. Macrophage activation syndrome [11] associated with autoimmune diseases.
2. Malignancy associated HLH [12] (especially lymphoma-associated haemophagocytic syndrome).
3. Infection associated HLH [13] (IAHS).

IAHS are most commonly associated with viral infections, which are the focus of this review. IAHS can also be caused by bacterial infections including mycobacteria and spirochetes as well as fungal and parasitic pathogens [1]. A review of the published cases in 219 children diagnosed with IAHS before 1996 [12] found that more than half were from the Far East. EBV was the triggering virus in 74% of the children in whom an infectious agent was identified. Overall mortality was 52% but was higher (73%) in patients with EBV–HPS.

PATHOPHYSIOLOGY

Haemophagocytic disorders arise from defects in critical regulatory pathways responsible for the natural termination of immune and inflammatory responses with a subsequent failure of a homeostatic removal of cells that are superfluous or dangerous to the host organism. The role of granule (perforin/granzymes)-mediated cytotoxicity is important in both the killing of infected cells and the termination of the immune response [14]. Genetic HPS can be attributed to a defect in the mechanism of granule (perforin/granzymes)-mediated cytotoxicity. Several genetic loci related to the activity of perforin/granzymes granules have been implicated in the pathophysiology of genetic HPS [15]. A defective triggering of apoptosis in FHLH has also been described in reference [16]. Specific genes or mutations associated with primary HPS include the PRF1 gene (perforin), the Munc 13-4 family of genes, the syntaxin 11 gene and the SH2-domain containing gene 1A.

The pathophysiology of acquired HPS is not fully understood. It certainly involves the interaction between T cells and macrophages but this does not exclude a genetic predisposition in affected cases.

The persistent activation of lymphocytes is the result of an uncontrolled immune response causing a hypersecretion of pro-inflammatory cytokines such as IFN\(\gamma\) [17], TNF\(\alpha\) [18], IL-6 [19], IL-8, IL-10 [18], IL-16 [20], IL-18 [21] and macrophage-colony-stimulating factor (M-CSF). IL-18 appears to play a crucial role particularly in autoimmune related HPS. In addition, higher levels of IFN\(\gamma\) and IL-10 are associated with a worse prognosis in childhood HPS [22]. The activation of T lymphocytes also results in an elevation of soluble IL-2 receptor [23] which is one of the diagnostic criteria of HPS and correlates with prognosis [24]. Furthermore, the presence of a specific TNF\(\alpha\) polymorphism has been associated with
an increased susceptibility to reactive HPS in certain Asian populations [25].

The proliferation of histiocytes is characterised by an up-regulation of adhesion and MHC Class I and II molecules [26] on monocytes/macrophages and expansion of inflammatory monocytes (increase in CD14/CD16 expression [27]).

The persistent activation of lymphocytes [28] and proliferation of histiocytes leads to organ infiltration and hemophagocytosis of various blood cells by macrophages present in bone marrow, lymph nodes and spleen.

**CLINICAL PRESENTATION AND DIAGNOSIS**

Diagnosis of HPS relies on specific clinical, laboratory, and histopathological findings proposed by the Histiocyte Society in 1991 [29] and updated in 2004 [30] (Table 2).

The main symptoms and signs of HPS are prolonged high fever, splenomegaly and cytopenias involving more than two cell lines. Less frequently observed clinical findings include jaundice, hepatomegaly, lymphadenopathy, rash and neurological signs (Table 3). Common laboratory findings result from prominent liver dysfunction [31]: low fibrinogen levels, high bilirubin levels, elevated serum transaminases, elevated prothrombin and partial thromboplastin times. High triglyceride levels are common in HPS and are therefore included in the diagnostic criteria. In a study of 28 patients with secondary HPS, 68% had hypertriglyceridaemia at diagnosis or at some time during the disease process and triglyceride levels subsequently decreased with successful treatment of HPS [32]. An often striking elevation of ferritin [33] levels is characteristic though it can be found in other diseases. A study from Texas found that a ferritin level above 10 000 μg/L was 90% sensitive and 96% specific for HPS [34]. Two other main diagnostic parameters are an increased plasma concentration of the alpha chain of the IL-2 receptor (sCD25) and impaired NK cell activity.

Typical histopathologic findings include activated macrophages with engulfed leukocytes, erythrocytes, platelets and their precursor cells. The haemophagocytosis can be seen in any organ but is particularly common in bone marrow, lymph nodes, liver and spleen eventually resulting in organomegaly and organ failure. At presentation, haemophagocytosis is only found in a minority of cases, but can be more easily detected as the syndrome progresses. Therefore, if haemophagocytosis is absent in initial biopsy specimens, the biopsy may need to be repeated in cases with high suspicion.

**Table 2. Diagnostic guidelines for hemophagocytic syndrome (HLH-04)**

The diagnosis of HPS is established if one or two of the following criteria are fulfilled:

- A molecular diagnosis consistent with HPS (i.e., PRF mutations, SAP mutations, MUNC13-4 mutations)
- Five out of eight of the following criteria
  - Clinical = Fever
  - Splenomegaly
  - Laboratory = Cytopenia (affecting > 2 cell lineages, hemoglobin ≤ 9 g/dl, platelets < 100 000/μl, neutrophils < 1000/μl)
  - Elevated triglyceride levels (≥ 265 mg/dl) and/or low fibrinogen levels (≤ 150 mg/dl)
  - Elevated ferritin levels (≥ 500 ng/ml)*
  -Histopathology = Hemophagocytosis without evidence of malignancy
  - Biologic markers = Low or absent NK cell cytotoxicity*
  - Elevated soluble CD25 (IL-2Rα chain; ≥ 2400U/ml)*

*Criteria added to the previous HLH diagnostic guidelines.
Once a diagnosis of HPS is established, a search for an underlying disease (genetic, rheumatologic or malignant disease) and a possible infectious trigger should be performed.

**TREATMENT**

HPS is frequently fatal if not treated promptly. As early therapy for HPS can be life saving and some of the diagnostic criteria may only become apparent late in disease it is not necessary to fulfil all diagnostic criteria before initiating therapy.

Treatment is based on the control of the cytokine storm and the cellular proliferation. In IAHS, treatment of the underlying infectious trigger is not sufficient to control the disease especially if HPS is associated with EBV. Immunochemotherapy as proposed by the Histiocyte Society (with the HLH-94 protocol [35,36] and subsequently the HLH-04 protocol [30]) consists of combination therapy with etoposide, dexamethasone and cyclosporine A as well as, in selected patients, intrathecal therapy with methotrexate and corticosteroids. The HLH-94 protocol was found to be highly effective in an early series of 17 cases of EBV–HPS [37]. The efficacy of HLH-94 was later confirmed by a large series including 47 patients of EBV–HPS [38] where none of the 33 patients receiving more than four doses of etoposide died. The prompt use of etoposide (less than 4 weeks after diagnosis) greatly improves the outcome in both pediatric [38] and adult patients [39]. The use of cyclosporine in treating HPS was first suggested by Oyama et al., in 1989 [40] when it was found to reduce the rate of fatal infections associated with neutropenia.

Although these immunomodulating chemotherapies are effective, they are commonly associated with side effects, most of which are more pronounced following prolonged courses of treatment. Cyclosporine is associated with severe headaches, hypertension, seizures and renal impairment. Corticosteroids have many well-described adverse effects, including hyperglycemia, fluid retention, hypertension and weight gain. Etoposide is associated with myelosuppression and development of secondary leukemia.

Intravenous gamma immunoglobulins (IVIG) [41] used with or without corticosteroids to treat HPS are usually not effective as monotherapy. Seventeen out of 21 patients treated with IVIG ± corticosteroids had to be switched to an etoposide-based regimen to better control the disease [38]. The 4 year survival was 68% for the IVIG/corticosteroids group, compared to 86% for the group that received an etoposide containing regimen as first line therapy. The use of growth factors such as granulocyte (G)-CSF or granulocyte monocyte (GM)-CSF is generally not recommended as they can exacerbate HPS [42].

Haematopoietic cell transplantation (HSCT) is recommended for patients with genetic forms and for patients with recurrent, persistent or refractory severe disease. HSCT has greatly improved the survival of FHLH. A retrospective review of FHLH 25 years ago [43] described a mean survival of less than a month after onset of symptoms and a 1 year overall survival of less than 5%. Currently, definitive treatment and potential cure of FHLH is only achieved by HSCT with projected 5 year survival rates [44] ranging from 50% to 70%. In 1996, Arico et al. [45] reviewed 122 patients with FHLH. Bone marrow transplantation (BMT) recipients had a significantly superior outcome in comparison with non-transplanted patients with a 66% versus 10.1% survival rate. Combining both, chemotherapy and BMT treated patients; the probability of survival at 3 years was 55% for all cases.

**VIRAL INFECTIONS ASSOCIATED WITH HPS**

**EBV**

**Epidemiology**

Epstein-Barr virus (EBV) is a ubiquitous herpesvirus associated with most cases of infection associated HPS [46]. The epidemiology of EBV associated HPS/HLH (EBV–HPS or EBV–HLH) is not well known. EBV–HPS has a higher incidence in Asian countries where each year in Japan, 25 cases of EBV HPS are diagnosed with female predominance and a peak incidence between 1 and 2 years of age [47]. The higher incidence rates in Asian countries are theorised to be due to a more pathogenic viral strain of EBV [48] genetically similar to viral strains obtained from nasopharyngeal carcinoma cell lines. EBV–HPS has been described in Western countries and the prevalence in non-Asian populations may be underestimated [49–51]. Information on the epidemiology of EBV–HPS in adults is lacking.
Pathophysiology

Primary EBV infection is usually asymptomatic except for infectious mononucleosis [52] (IM), seen commonly in children and young adults. During primary infection, EBV typically infects and replicates in B cells. After primary infection, EBV-specific T cells (cytotoxic T cells or CTLs) are usually acquired to regulate EBV-infected B cells and induce memory B cells. While EBV has a well-described tropism for B cells and nasopharyngeal epithelial cells, the invasion of non-B cell populations plays an important role in the pathogenesis of several severe EBV related diseases, with disease manifestations generally depending on the type of EBV-infected cell [53] and the state of the host immunity. In rare cases, for instance, EBV infects T and natural killer (T/NK) cells and can induce persistent EBV infection in these cells. Refractory and severe EBV disease results from either (i) chronic active EBV infection [54] (ii) acute fulminant EBV HPS [55] (iii) lymphoproliferative disorders (T/NK cell leukemia/lymphoma [56] or lymphoma associated haemophagocytic syndrome [57]). In chronic EBV infection, primarily CD4+ T cells or NK cells are affected. A dysfunction in T/NK cells results in a decrease in EBV-specific CTLs and subsequent EBV-associated T/NK cell lymphoproliferative disease. In EBV-HPS, EBV infects primarily CD8+ cells [58] and results in a cytokine storm with the release of proinflammatory and Th1-type cytokines [59] including TNFα and IFNγ, resulting in the secondary activation of histiocytes and macrophages [53].

The cytokine response seen in EBV–HPS tends to be much more pronounced than the one observed in non-EBV–HPS [60].

Although EBV–HPS probably develops as a result of some element of immune dysfunction, the precise characteristics of host vulnerability to EBV are largely unknown, and the majority of EBV–HPS cases occur in apparently immunocompetent and previously healthy children, adolescents and young adults. Cases of EBV–HPS can also be seen in the setting of established immune deficiencies such as FHLH [43] and XLP [61].

Diagnosis [62]

Serological testing can help to determine if the EBV–HPS occurred in the setting of primary infection or is the result of a reactivation process. In a recent epidemiological study from Japan, the vast majority of EBV–HPS cases occurred in children with primary infection. Reactivation was considered a risk factor for worse outcome [4]. However, serologic methods carry some limitations. Real-time PCR allows the quantitative measurement of EBV viral load. Even though the vast majority of EBV in peripheral blood is found within leukocytes, EBV PCR of whole blood and serum are considered to adequately reflect the EBV load in terms of viral replication [63]. EBV PCR levels in EBV–HPS are usually higher than those seen in EBV–IM [64]. EBV viral load is considered a prognostic factor and a measure of the efficacy of treatment [65] in EBV–HPS.

Various cell sorting techniques can be used to determine if T cells or NK cells are primarily involved and to confirm the diagnosis [50]. Clonality should be determined by cytogenetic analysis, T-cell receptor gene rearrangements, or Southern blot analysis for fused termini of the EBV genome, utilising blood, bone marrow or other lymphoid tissues.

Genetic testing for inherited conditions linked to hemophagocytosis, such as familial HLH and XLP should be considered, particularly in young (<1 year of age) or male patients with EBV–HPS, when there is consanguinity between parents, when HPS is present in another sibling, or when HPS is relapsing or refractory.

Treatment

Mild cases of EBV–HPS are treated conservatively since spontaneous regression of EBV–HPS has been described in reference [66]. Antiviral therapy with acyclovir, ganciclovir or cidofovir is generally ineffective in IM and has provided disappointing results in EBV–HPS.

The optimal treatment strategy [67] for EBV–HPS consists of:

(i) Control of the cytokine storm resulting in multiorgan failure and coagulopathy. Antithymocyte globulins [68], splenectomy [69] and plasma exchange or blood exchange transfusion [70] have been used in the treatment of EBV–HPS.

(ii) Control of opportunistic infections particularly fungal and bacterial [71] infections in the setting of neutropenia.

(iii) Eradication of proliferating clonal and EBV containing T cells and NK cells. Immunosup-
pressive medications inhibiting overactive T and NK cell responses, in conjunction with chemotherapeutic agents targeting dividing lymphocytes and mononuclear phagocytes are typically used to treat EBV–HPS. Early treatment is associated with markedly improved survival [47]. Addition of agents that eliminate EBV infected B cells may decrease EBV viral loads and improve the efficacy of current therapeutic arsenal but are ineffective alone. Rituximab [72], a humanised anti-CD20 monoclonal antibody that targets mature B cells, was added to standard regimens to treat a few cases of EBV–HPS [73].

HSCT or BMT has become the treatment of choice for HLH as well as refractory cases of EBV–HPS [74]. EBV–HPS carries the worst prognosis among viral infections associated with HPS. However, with the use of HLH-94 and HLH-04 protocols and, if necessary, BMT, the prognosis of EBV–HPS has improved dramatically. In 78 patients with EBV–HPS treated between 1992 and 2001, 75.6% were alive following a median follow-up of 43 months [75]. 85% of these patients were treated with etoposide-based regimens, 15% with BMT. 20% experienced a relapse.

OTHER HERPESVIRUSES
Aside from EBV, the most common herpesviruses associated with HPS are CMV and HHV8.

CMV infection has been associated with HPS (CMV–AHS) in different settings. It has been observed in healthy patients [76,77], premature infants [78], patients with inflammatory bowel disease [79,80], rheumatological diseases [81,82], cancer [83] and in transplant recipients [84,85]. In a prospective study of 171 patients undergoing HSCT, 7 (4%) developed HPS with CMV being the most common trigger in 3 cases [86]. The use of CMV hyperimmune globulin, foscarnet or ganciclovir has been associated with recovery in selected cases [77,79–81,85]. Younger age may be associated with a worse prognosis, with fatal outcomes occurring in four of the five infants in the HLH Japanese registry with CMV–AHS diagnosed at less than a year old [87] (1986–2002).

HHV-8 has been associated with HPS, mostly in the setting of Kaposi’s sarcoma [88], multicentric Castleman’s disease [89] or lymphoproliferative disorder [90], in immunocompromised hosts (HIV [91], transplant [92]) and rarely in immunocompetent hosts [93,94]. In a prospective cohort of 44 patients with Castleman’s disease and HIV, 4 (9%) had HPS [89]. Interestingly, in this series the cytokine levels of many known inflammatory markers were not elevated; however, IL-8 and IFNγ were increased. In this study, all patients recovered after treatment with splenectomy, etoposide and rituximab [95] based regimens. Ganciclovir and foscarnet have also been associated with recovery in some HHV8–HPS cases.

All other herpesviruses [96–99] with the exception of HHV-7 have been associated with HPS.

HIV
HPS associated with HIV [100] infection is seen in several different settings. Cases have been reported in acute or late HIV infection, in conjunction with immune reconstitution inflammatory syndromes (IRIS), in the setting of infections (both opportunistic and non opportunistic) [101] or malignancies.

Even though hemophagocytosis was observed in 20% of 56 autopsy cases of HIV positive patients [102], clinically apparent HPS is rare in this setting. This association, however, may be underreported and underdiagnosed since HIV and HPS share many similar clinical and biological findings.

To the best of our knowledge, 9 cases of acute HIV with HPS have been reported in the literature [103–105]. There was a male predominance (M:F = 8:1) with a median age at onset of 27. Almost two thirds had a CD4 count < 200 cells/μl with a range of 63–500 cells/μl. Treatment consisted mainly of IVIG (n = 3) and steroids (n = 2); highly active antiretroviral therapy (HAART) [104,105] was only initiated during the acute phase in 2 cases. All cases reported in the literature survived.

In a review of 39 HIV–HPS cases [106] by Bhatia and colleagues, 82% were male with a median age of 38 years (range 26–59). 80% had a CD4 less than 200 cells/μl with a mean of 132 cells/μl. A lower CD4 count was associated with a worse prognosis. Eleven patients had no opportunistic infection or malignancy suggesting a possible pathogenetic role of HIV itself. Most of the patients presented with fever, two thirds had hepatomegaly and more than half had splenomegaly; pancytopenia was very common. When information was available (n = 15) regarding treatment, only three received HAART and only one responded [107]...
to HAART. Two received chemotherapy inconsistent with the HLH protocol, six received IVIG, five received corticosteroids and two underwent splenectomy. Overall, recovery was noted in only 28% of patients with half of the deaths occurring within 1 month following the diagnosis of HPS.

Four cases of HIV–AHS have been described in the setting of IRIS [108–110]. All patients were male and reported ages ranged from 33 to 45 years. Symptoms occurred within 1 to 3 weeks following initiation of HAART. IRIS HIV–HPS has occurred in the setting of histoplasmosis [110] as well as Hodgkin’s lymphoma [109]. Both patients with Hodgkin’s lymphoma were treated with chemotherapy [109] and one of them survived. The patient with histoplasmosis survived following treatment with IVIG and amphotericin [110]. The fourth patient had a fatal outcome despite treatment with etoposide and corticosteroids [108].

INFLUENZA
The association of HPS with influenza has been described in both immunocompromised [111–114] and in immunocompetent patients [115,116]. In a prospective pediatric study [117], one fatal case of HPS was observed among 32 children hospitalised with seasonal influenza. Influenza associated HPS has been seen with seasonal [111–117], avian [118,119] and swine (non-pandemic) influenza [120].

Patients with severe H5N1 (avian) influenza infection have symptoms and laboratory findings similar to those seen in HPS, mainly encephalitis [121], organ dysfunction with haemophagocytosis [122], bone marrow failure [122,123] and cytokine storm [124,125]. Haemophagocytosis seen on autopsy and biopsy is the most common characteristic pathological finding [119,125,126]. The haemagglutinin found in H5N1 viruses may suppress perforin expression and reduce cytotoxicity of human CD8+ T cells including their ability to kill H5-bearing cells leading to marked lymphoproliferation and IFN-γ hyperproduction with macrophage overactivation [127]. With some viruses being resistant to amantadine [128,129] and less commonly, even to certain neuraminidase inhibitors [130,131] and since many similarities exist between HPS and severe flu infection, some authors have speculated that the use of a modified HLH-94 protocol [132] with shorter course of etoposide and dexamethasone should be considered in H5N1 infections associated with HPS.

One fatal case of swine flu associated HPS in an immunocompetent patient has been reported in 1998 [120]. While it is possible that some fatal cases of the novel (swine-origin) H1N1 pandemic strain could also be due to HPS, it is currently unclear how much HPS contributes to the pathology of severe novel H1N1 infection.

PARVOVIRUS
Approximately 30 cases [70,133–139] of parvovirus B19 infection have been associated with HPS. The most common underlying disease was hereditary spherocytosis. More than half of the patients were female and most of the cases were seen in adolescents and adults. The majority of patients with parvovirus-associated HPS survived without any specific therapy suggesting that parvovirus-associated HPS carries a better prognosis than other VAHS.

VIRAL HEPATITIS
Fulminant viral hepatitis may mimic but can also be a cause of a true HPS. Hepatitis A virus is more commonly associated with HPS than the other hepatitis virus including hepatitis B or hepatitis C. Fifteen cases [140–142] of HAV–HPS have been described in the literature; all except 4 cases were reported from Asia. The age range was 3–49 years with a median age of 28 and no gender predilection was noted. Three patients had concurrent rheumatologic diseases (systemic juvenile idiopathic arthritis, Still’s disease), two patients also had hepatitis C and one patient was an alcoholic. Four patients received no specific treatment but survived. Most commonly, treatment consisted of corticosteroids ± IVIG. Eleven out of the 15 cases had a favourable outcome.

OTHER VIRUSES
There are 12 cases of enterovirus-associated HPS that have been described in the English literature [143]: 5 cases occurred in infants less than 1 year of age, the oldest patient was 18 years old. Underlying diseases were found in 4 cases (Hodgkin’s lymphoma, non–Hodgkin’s lymphoma, acute lymphoblastic leukemia and juvenile arthritis) and was associated with a higher fatality rate (75%). Ten patients received IVIG, six in combination with steroids. Overall, seven patients survived.
Other viruses found to be associated with HPS include: adenovirus, BK virus, measles, mumps, rubella, parainfluenza virus, dengue, hantavirus, hemorrhagic fever and severe acute respiratory syndrome associated coronavirus [1].

CONCLUSION
Haemophagocytic syndrome is a rare, often fatal disease frequently triggered by viral infections, most notably EBV. The treatment of the underlying infectious trigger alone tends to lead to suboptimal results. Early recognition and prompt treatment have been shown to improve prognosis with severe cases often requiring chemotherapy with or without BMT. Clinicians, therefore, need to be alert and suspect this entity in patients with high fever not responding to broad-spectrum antibiotics, organomegaly and characteristic laboratory and histologic findings.

REFERENCE
1. Rouphael NG, Talati NJ, Vaughan C, Cunningham K, Moreira R, Gould C. Infections associated with haemophagocytic syndrome. Lancet Infect Dis 2007; 7: 814–822.
2. Scott R, Robb-Smith A. Histiocytic medullary reticulosis. Lancet 1939; 2: 194–198.
3. Risdall RJ, McKenna RW, Nesbit ME, et al. Virus-associated haemophagocytic syndrome: a benign histiocytic proliferation distinct from malignant histiocytosis. Cancer 1979; 44: 993–1002.
4. Ishii E, Ohga S, Imashuku S, et al. Nationwide survey of hemophagocytic lymphohistiocytosis in Japan. Int J Hematol 2007; 86: 58–65.
5. Allen M, De Fusco C, Legrand F, et al. Familial hemophagocytic lymphohistiocytosis: how late can the onset be? Haematologica 2001; 86: 499–503.
6. Henter JI, Ehrnst A, Andersson J, Elinder G. Familial hemophagocytic lymphohistiocytosis and viral infections. Acta Paediatr 1993; 82: 369–372.
7. Verbsky JW, Grossman WJ. Hemophagocytic lymphohistiocytosis: diagnosis, pathophysiology, treatment, and future perspectives. Ann Med 2006; 38: 20–31.
8. Farquhar J, Claireaux A. Familial haemophagocytic reticulosis. Arch Dis Child 1952; 27: 519–525.
9. Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial haemophagocytic lymphohistiocytosis. Acta Paediatr Scand 1991; 80: 428–435.
10. Ishii E, Ohga S, Tanimura M, et al. Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH Study Group. Med Pediatr Oncol 1998; 30: 276–283.
11. Dhote R, Simon J, Papo T, et al. Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum 2003; 49: 633–639.
12. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am 1998; 12: 435–444.
13. Fisman DN. Hemophagocytic syndromes and infection. Emerg Infect Dis 2006; 6: 601–608.
14. de Saint Basile G, Fischer A. Defective cytotoxic granule-mediated cell death pathway impairs T lymphocyte homeostasis. Curr Opin Rheumatol 2003; 15: 436–445.
15. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 1999; 286: 1957–1959.
16. Fadel B, Orrenius S, Henter JI. Familial hemophagocytic lymphohistiocytosis: too little cell death can seriously damage your health. Leuk Lymphoma 2001; 42: 13–20.
17. Ohga S, Matsuzaki A, Nishizaki M, et al. Inflammatory cytokines in virus-associated hemophagocytic syndrome. Interferon-gamma as a sensitive indicator of disease activity. Am J Pediatr Hematol Oncol 1993; 15: 291–298.
18. Osugi Y, Hara J, Tagawa S, et al. Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 1997; 89: 4100–4103.
19. Imashuku S, Hibi S, Fujiwara F, Todo S. Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis. Br J Haematol 1996; 93: 803–807.
20. Takada H, Ohga S, Mizuno Y, Nomura A, Hara T. Increased IL-16 levels in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol 2004; 26: 567–573.
21. Takada H, Nomura A, Ohga S, Hara T. Interleukin-18 in hemophagocytic lymphohistiocytosis. Leuk Lymphoma 2001; 42: 21–28.
22. Tang Y, Xu X, Song H, et al. Early diagnostic and prognostic significance of a specific Th1/Th2 cytokine pattern in children with haemophagocytic syndrome. Br J Haematol 2008; 143: 84–91.
23. Komp DM, Buckley PJ, McNamara J, van Hoff J. Soluble interleukin-2 receptor in hemophagocytic histiocytes: searching for markers of disease activity. Pediatr Hematol Oncol 1989; 6: 253–264.
24. Imashuku S, Hibi S, Sako M, et al. Soluble interleukin-2 receptor: a useful prognostic factor for patients with hemophagocytic lymphohistiocytosis. Blood 1995; 86: 4706–4707.
25. Chang YH, Lee DS, Jo HS, et al. Tumor necrosis factor alpha promoter polymorphism associated with increased susceptibility to secondary hemophagocytic lymphohistiocytosis in the Korean population. Cytokine 2006; 36: 45–50.

26. Kereveur A, McIlroy D, Samri A, Oksenhendler E, Clauvel JP, Autran B. Up-regulation of adhesion and MHC molecules on splenic monocyte/macrophages in adult haemophagocytic syndrome. Br J Haematol 1999; 104: 871–877.

27. Emminger W, Zlabinger GJ, Fritsch G, Urbanek R, et al. Analysis of latent membrane protein 1 in hemophagocytic lymphohistiocytosis. Eur J Immunol 2001; 31: 1716–1719.

28. de Saint Basile G, Fischer A. The role of cytotoxicity in lymphocyte homeostasis. Curr Opin Immunol 2001; 13: 549–554.

29. Henter JJ, Elinder G, Ost A. Diagnostic guidelines for hemophagocytic lymphohistiocytosis. The FHL Study Group of the Histiocyte Society. Semin Oncol 1991; 18: 29–33.

30. Tokuyasu K, Hara Y, Matsumoto Y, et al. Hypertrophic cardiomyopathy with mid-ventricular obstruction and splenic infarction associated with paroxysmal atrial fibrillation: a case report. J Cardiol 1999; 34: 273–277.

31. de Kerguenec C, Hillaire S, Molinie V, et al. Hyperferritinemia in reactive hemophagocytic syndrome: a study of 30 cases. Am J Gastroenterol 2001; 96: 852–857.

32. Okamoto M, Yamaguchi H, Isobe Y, et al. Analysis of triglyceride value in the diagnosis and treatment response of secondary hemophagocytic syndrome. Intern Med 2009; 48: 775–781.

33. Koduri PR, Carandang G, DeMarais P, Patel AR. Hyperferritinaemia in reactive hemophagocytic syndrome report of four adult cases. Am J Hematol 1995; 49: 247–249.

34. Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2008; 50: 1227–1235.

35. Henter JJ, Arico M, Egeler RM, et al. HLH-94: a treatment protocol for hemophagocytic lymphohistiocytosis. HLH study Group of the Histiocyte Society. Med Pediatr Oncol 1997; 28: 342–347.

36. Henter JJ, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunomethodology and bone marrow transplantation. Blood 2002; 100: 2367–2373.

37. Imashuku S, Hibi S, Ohara T, et al. Effective control of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis with immunomethochemistry. Histiocyte Society. Blood 1999; 93: 1869–1874.
lymphohistiocytosis in children of non-Asian origin. Pediatr Blood Cancer 2009; 53: 184–190.

52. Christensson B, Bracconier JH, Winqvist I, Relander T, Dick M. Fulminant course of infectious mononucleosis with virus-associated hemophagocytic syndrome. Scand J Infect Dis 1987; 19: 373–379.

53. Kasahara Y, Yachie A. Cell type specific infection of Epstein-Barr virus (EBV) in EBV-associated hemophagocytic lymphohistiocytosis and chronic active EBV infection. Crit Rev Oncol Hematol 2002; 44: 283–94.

54. Ohshima K, Suzumiya J, Sugihara M, Nagafuchi S, Ohga S, Kikuchi M. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome. Pathol Int 1998; 48: 934–943.

55. Lindemann TL, Greene JS. Persistent cervical lymphadenopathy in an adolescent with Epstein-Barr induced hemophagocytic syndrome: manifestations of a rare but often fatal disease. Int J Pediatr Otorhinolaryngol 2005; 69: 1011–1014.

56. Akashi K, Mizuno S. Epstein-Barr virus-infected natural killer cell leukemia. Leuk Lymphoma 2000; 40: 57–66.

57. Su IJ, Wang CH, Cheng AL, Chen RL. Hemophagocytic syndrome in Epstein-Barr virus-associated T-lymphoproliferative disorders: disease spectrum, pathogenesis, and management. Leuk Lymphoma 1995; 19: 401–406.

58. Wada T, Kurokawa T, Toma T, et al. Immunophenotypic analysis of Epstein-Barr virus (EBV)-infected CD8+ T cells in a patient with EBV-associated hemophagocytic lymphohistiocytosis. Eur J Haematol 2007; 79: 72–75.

59. Chuan HC, Lay JD, Hsieh WC, et al. Epstein-Barr virus LMP1 inhibits the expression of SAP gene and upregulates Th1 cytokines in the pathogenesis of hemophagocytic syndrome. Blood 2005; 106: 3090–3096.

60. Imashuku S, Hibi S, Tabata Y, et al. Biomarker and morphological characteristics of Epstein-Barr virus-related hemophagocytic lymphohistiocytosis. Med Pediatr Oncol 1998; 31: 131–137.

61. Morra M, Howie D, Grande MS, et al. X-linked lymphoproliferative disease: a progressive immunodeficiency. Ann Rev Immunol 2001; 19: 657–682.

62. Kimura H, Ito Y, Suzuki R, Nishiyama Y. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Rev Med Virol 2008; 18: 305–319.

63. Kimura H, Nishikawa K, Hoshino Y, Sofue A, Nishiyama Y, Morishima T. Monitoring of cell-free viral DNA in primary Epstein-Barr virus infection. Med Microbiol Immunol (Berl) 2000; 188: 197–202.
77. Oloomi Z, Moayeri H. Cytomegalovirus infection-associated hemophagocytic syndrome. *Arch Iran Med* 2006; 9: 284–287.

78. Maruyama K, Koizumi T, Hirato J. Cytomegalovirus infections associated hemophagocytic lymphohistiocytosis in a premature infant. *Pediatr Int* 2006; 48: 648–650.

79. Kohara MM, Blum RN. Cytomegalovirus ileitis and human herpesvirus-8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome. *Clin Infect Dis* 2006; 42: 733–734.

80. Koketsu S, Watanabe T, Hori N, Umetani N, Taka-zawa Y, Nagawa H. Hemophagocytic syndrome caused by fulminant ulcerative colitis and cytomegalovirus infection: report of a case. *Dis Colon Rectum* 2004; 47: 1250–1253; discussion 3–5.

81. Amenomori M, Migita K, Miyashita T, et al. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still’s disease. *Clin Exp Rheumatol* 2005; 23: 100–102.

82. Sakamoto O, Ando M, Yoshimatsu S, Kohrogi H, Suga M, Ando M. Systemic lupus erythematosus complicated by cytomegalovirus-induced hemophagocytic syndrome and colitis. *Intern Med* 2002; 41: 151–155.

83. Devecioglu O, Anak S, Atay D, et al. Pediatric acute lymphoblastic leukemia complicated by secondary hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2009; 53: 491–492.

84. Sato M, Matsushima T, Takada S, et al. Fulminant, CMV-associated, haemophagocytic syndrome following unrelated bone marrow transplantation. *Bone Marrow Transplant* 1998; 22: 1219–1222.

85. Hardikar W, Pang K, Al-Hebbi H, Curtis N, Couper R. Successful treatment of cytomegalovirus-associated haemophagocytic syndrome following paediatric orthotopic liver transplantation. *J Paediatr Child Health* 2006; 42: 389–391.

86. Abdelkefi A, Ben Jamil W, Torjman L, et al. Hemophagocytic syndrome after hematopoietic stem cell transplantation: a prospective observational study. *Int J Hematol* 2009; 89: 368–373.

87. Imashuku S, Ueda I, Teramura T, et al. Occurrence of haemophagocytic lymphohistiocytosis at less than 1 year of age: analysis of 96 patients. *Eur J Pediatr* 2005; 164: 315–319.

88. Uneda S, Murata S, Sonoki T, Matsuoka H, Naka-kuma H. Successful treatment with liposomal doxorubicin for widespread Kaposi’s sarcoma and human herpesvirus-8 related severe hemophagocytic syndrome in a patient with acquired immunodeficiency syndrome. *Int J Hematol* 2009; 89: 195–200.

89. Stebbing J, Ngan S, Ibrahim H, et al. The successful treatment of haemophagocytic syndrome in patients with human immunodeficiency virus-associated multi-centric Castleman’s disease. *Clin Exp Immunol* 2008; 154: 399–405.

90. Pastore RD, Chadburn A, Kripas C, Schattner EJ. Novel association of haemophagocytic syndrome with Kaposi’s sarcoma-associated herpesvirus-related primary effusion lymphoma. *Br J Haematol* 2000; 111: 1112–1115.

91. Fardet L, Blum L, Kerob D, et al. Human herpesvirus 8-associated hemophagocytic lymphohistiocytosis in human immunodeficiency virus-infected patients. *Clin Infect Dis* 2003; 37: 285–291.

92. Bossini N, Sandrini S, Setti G, et al. Successful treatment with liposomal doxorubicin and foscarnet in a patient with widespread Kaposi’s sarcoma and human herpes virus 8-related, serious hemophagocytic syndrome, after renal transplantation. *G Ital Nefrol* 2005; 22: 281–286.

93. Re A, Facchetti F, Borlonghi E, et al. Fatal hemophagocytic syndrome related to active human herpesvirus-8/Kaposi sarcoma-associated herpesvirus infection in human immunodeficiency virus-negative, non-transplant patients without related malignancies. *Eur J Haematol* 2007; 78: 361–364.

94. Grossman WJ, Radhi M, Schauer D, Gerday E, Grose C, Goldman FD. Development of hemophagocytic lymphohistiocytosis in triplets infected with HHV-8. *Blood* 2005; 106: 1203–1206.

95. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. *Blood* 2001; 98: 3473–3475.

96. Yamada K, Yamamoto Y, Uchiyama A, et al. Successful treatment of neonatal herpes simplex-type 1 infection complicated by hemophagocytic lymphohistiocytosis and acute liver failure. *Tohoku J Exp Med* 2008; 214: 1–5.

97. Ramasamy K, Lim ZY, Savvas M, et al. Disseminated herpes virus (HSV-2) infection with rhabdomyolysis and hemophagocytic lymphohistiocytosis in a patient with bone marrow failure syndrome. *Ann Hematol* 2006; 85: 629–630.

98. van der Werff Ten Bosch JE, Kollen WJ, Ball LM, et al. Atypical varicella zoster infection associated with hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2009; 53: 226–228.

99. Tanaka H, Nishimura T, Hakui M, Sugimoto H, Morishita Y, Nagawa H. Hemophagocytic syndrome caused by fulminant ulcerative colitis and cytomegalovirus infection: report of a case. *Clin Infect Dis* 2006; 42: 733–734.

100. Doyle T, Bhagani S, Cwynarski K. Haemophagocytic syndrome following unrelated bone marrow transplantation. *Bone Marrow Transplant* 1998; 22: 1219–1222.

101. Albrecht H, Schafer H, Stellbrink HJ, Greten H. Epstein-Barr virus–Associated hemophagocytic syndrome.
syndrome. A cause of fever of unknown origin in human immunodeficiency virus infection. *Arch Pathol Lab Med* 1997; **121**: 853–858.

102. Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. *Arch Pathol Lab Med* 1985; **109**: 727–734.

103. Sun HY, Chen MY, Fang CT, Hsieh SM, Hung CC, Chang SC. Hemophagocytic lymphohistiocytosis: an unusual initial presentation of acute HIV infection. *J Acquir Immune Defic Syndr* 2004; **37**: 1539–1540.

104. Castilletti C, Preziosi R, Bernardini G, *et al.* Hemophagocytic syndrome in a patient with acute human immunodeficiency virus infection. *Clin Infect Dis* 2004; **38**: 1792–1793.

105. Park KH, Yu HS, Jung SI, Shin DH, Shin JH. Acute human immunodeficiency virus syndrome presenting with hemophagocytic lymphohistiocytosis. *Yonsei Med J* 2008; **49**: 325–328.

106. Bhatia S, Bauer F, Bilgrami SA. Candidiasis-associated hemophagocytic lymphohistiocytosis in a patient infected with human immunodeficiency virus. *Clin Infect Dis* 2003; **37**: e161–e166.

107. Gotoh M, Matsuda J, Goohki K, Sanaka T, Kawa sugi K. Successful recovery from human immunodeficiency virus (HIV)-associated hemophagocytic syndrome treated with highly active anti-retroviral therapy in a patient with HIV infection. *Br J Haematol* 2001; **112**: 1090.

108. Huang DB, Wu JJ, Hamill RJ. Reactive hemophagocytosis associated with the initiation of highly active antiretroviral therapy (HAART) in a patient with AIDS. *Scand J Infect Dis* 2004; **36**: 516–519.

109. Cuttetoil M, Pascau A, Baur Chaubert AS, *et al.* Hemophagocytic syndrome after highly active antiretroviral therapy initiation: a life-threatening event related to immune restoration inflammatory syndrome? *AIDS* 2008; **22**: 549–551.

110. De Lavaissiere M, Manceron V, Bouree P, *et al.* Reconstitution inflammatory syndrome related to histoplasmosis, with a hemophagocytic syndrome in HIV infection. *J Infect* 2009; **58**: 245–247.

111. Potter MN, Foot AB, Oakhill A. Influenza A and the virus associated haemophagocytic syndrome: cluster of three cases in children with acute leukaemia. *J Clin Pathol* 1991; **44**: 297–299.

112. Imashuku S. Differential diagnosis of hemophagocytic syndrome: underlying disorders and selection of the most effective treatment. *Int J Hematol* 1997; **66**: 135–151.

113. Cunney RJ, Bialachowski A, Thornley D, Smaill FM, Pennie RA. An outbreak of influenza A in a neonatal intensive care unit. *Infect Control Hosp Epidemiol* 2000; **21**: 449–454.

114. Ando M, Miyazaki E, Hiroshige S, *et al.* Virus associated hemophagocytic syndrome accompanied by acute respiratory failure caused by influenza A (H3N2). *Intern Med* 2006; **45**: 1183–1186.

115. Watanabe T, Okazaki E, Shibuya H. Influenza A virus-associated encephalopathy with hemophagocytic syndrome. *Eur J Pediatr* 2003; **162**: 799–800.

116. Mou SS, Nakagawa TA, Riemer EC, McLean TW, Hines MH, Shetty AK. Hemophagocytic lymphohistiocytosis complicating influenza a infection. *Pediatrics* 2006; **118**: e216–e219.

117. Samransamruajkit R, Hiranrat T, Chieochansin T, *et al.* Prevalence, clinical presentations and complications among hospitalized children with influenza pneumonia. *Jpn J Infect Dis* 2008; **61**: 446–449.

118. To KF, Chan PK, Chan KF, *et al.* Pathology of fatal human infection associated with avian influenza A H5N1 virus. *J Med Virol* 2001; **63**: 242–246.

119. Zhang Z, Zhang J, Huang K, *et al.* Systemic infection of avian influenza A virus H5N1 subtype in humans. *Hum Pathol* 2009; **40**: 735–739.

120. Kimura K, Adlakha A, Simon PM. Fatal case of swine influenza virus in an immunocompetent host. *Mayo Clin Proc* 1998; **73**: 243–245.

121. de Jong MD, Bach VC, Phan TQ, *et al.* Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. *N Engl J Med* 2005; **352**: 686–691.

122. Chokephaibulkit K, Uiprasertkul M, Puthavathana P, *et al.* A child with avian influenza A (H5N1) infection. *Pediatr Infect Dis J* 2005; **24**: 162–166.

123. Peiris JS, Yu WC, Leung CW, *et al.* Re-emergence of fatal human influenza A subtype H5N1 disease. *Lancet* 2004; **363**: 617–619.

124. Cheung CY, Poon LL, Lau AS, *et al.* Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease? *Lancet* 2002; **360**: 1831–1817.

125. Chan PK. Outbreak of avian influenza A(H5N1) virus infection in Hong Kong in 1997. *Clin Infect Dis* 2002; **34**(Suppl. 2): S58–S64.

126. Ng WF, To KF, Lam WW, Ng TK, Lee KC. The comparative pathology of severe acute respiratory syndrome and avian influenza A subtype H5N1—a review. *Hum Pathol* 2006; **37**: 381–390.

127. Hsieh SM, Chang SC. Insufficient perforin expression in CD8+ T cells in response to hemagglutinin from avian influenza (H5N1) virus. *J Immunol* 2006; **176**: 4530–4533.

128. Cheung CL, Rayner JM, Smith GJ, *et al.* Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. *J Infect Dis* 2006; **193**: 1626–1629.

129. Ilyushina NA, Govorkova EA, Webster RG. Detection of amantadine-resistant variants among avian
influenza viruses isolated in North America and Asia. *Virology* 2005; **341**: 102–106.

130. Le QM, Kiso M, Someya K, *et al*. Avian flu: isolation of drug-resistant H5N1 virus. *Nature* 2005; **437**: 1108.

131. de Jong MD, Tran TT, Truong HK, *et al*. Oseltamivir resistance during treatment of influenza A (H5N1) infection. *N Engl J Med* 2005; **353**: 2667–2672.

132. Henter JI, Chow CB, Leung CW, Lau YL. Cytotoxic therapy for severe avian influenza A (H5N1) infection. *Lancet* 2006; **367**: 870–873.

133. Hermann J, Steinbach D, Lengemann J, Zintl F. Parvovirus B19 associated hemophagocytic syndrome in a patient with hereditary spherocytosis. *Klin Padiatr* 2003; **215**: 270–274.

134. Yilmaz S, Oren H, Demircioglu F, Firinci F, Korkmaz A, Irken G. Parvovirus B19: A cause for aplastic crisis and hemophagocytic lymphohistiocytosis. *Pediatr Blood Cancer* 2006; **47**: 8610.

135. Larroche C, Scieux C, Honderlick P, Piette AM, Morinet F, Bletry O. Spontaneous resolution of hemophagocytic syndrome associated with parvovirus B19 infection in an otherwise healthy adult. *Eur J Clin Microbiol Infect Dis* 2002; **21**: 739–742.

136. Dutta U, Mittal S, Ratho RK, Das A. Acute liver failure and severe hemophagocytosis secondary to parvovirus B19 infection. *Indian J Gastroenterol* 2005; **24**: 118–119.

137. Ardalan MR, Shoja MM, Tubbs RS, Esmaili H, Keyvani H. Postrenal transplant hemophagocytic lymphohistiocytosis and thrombotic microangiopathy associated with parvovirus B19 infection. *Am J Transplant* 2008; **8**: 1340–1344.

138. Miyakawa K, Ohsugi K, Sugahara S, Kuriyama C, Kikuchi A, Ohta M. Tsutsugamushi disease with hemophagocytosis complicated by Parvovirus B19 infection. *Nippon Naika Gakkai Zasshi* 2006; **95**: 2544–2546.

139. Watanabe M, Shibuya A, Okuno J, Maeda T, Tamama S, Saigenji K. Hepatitis A virus infection associated with hemophagocytic syndrome: report of two cases. *Intern Med* 2002; **41**: 1188–1192.

140. Tuon FF, Gomes VS, Amato VS, *et al*. Hemophagocytic syndrome associated with hepatitis A: case report and literature review. *Rev Inst Med Trop Sao Paulo* 2008; **50**: 123–127.

141. Russo RA, Rosenzweig SD, Katsicas MM. Hepatitis A-associated macrophage activation syndrome in children with systemic juvenile idiopathic arthritis: report of 2 cases. *J Rheumatol* 2008; **35**: 166–168.

142. Katsibardi K, Moschovi MA, Theodoridou M, *et al*. Enterovirus-associated hemophagocytic syndrome in children with malignancy: report of three cases and review of the literature. *Eur J Pediatr* 2008; **167**: 97–102.